Xiao Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiao Deng has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Bin Xiao
Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore 169608, Singapore
3 shared publicationsEng-King Tan
Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore 169608, Singapore; Duke-NUS Graduate Medical School, Singapore 169857, Singapore
2 shared publications- Eng-King Tan
National Neuroscience Institute, Singapore 308433, Singapore
2 shared publications Yew-Long Lo
National Neuroscience Institute
2 shared publicationsYing Hao
Health Service Research Unit, Division of Medicine, Singapore General Hospital, Singapore 169608, Singapore
2 shared publicationsAdeline Ng
Department of Neurology National Neuroscience Institute Singapore City Singapore
1 shared publication
Latest Publications
- 15 June 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (9) , 2874-2878
Parkinson's disease genome‐wide association study‐linked PARK16 variant is associated with a lower risk of cognitive impairment: A 4‐year observational study
Background and purpose: A genome‐wide association study‐linked variant (PARK16 rs6679073) modulates the risk of Parkinson's disease (PD). We postulate that there may be differences in clinical characteristics between PARK16 rs6679073 carriers and noncarriers. In a prospective study, we investigate the clinical characteristics between PARK16 rs6679073 A allele carriers and noncarriers over 4 years.Methods: A total of 204 PD patients, comprising 158 PARK16 rs6679073 A allele carriers and 46 noncarriers, were recruited. All patients underwent motor and nonmotor symptom and cognitive assessments yearly over 4 years.Results: PARK16 rs6679073 carriers were less likely to have mild cognitive impairment (MCI) compared to noncarriers at both baseline (48.1% vs. 67.4%, p = 0.027) and 4‐year follow‐up (29.3% vs. 58.6%, p = 0.007).Conclusions: PD PARK16 rs6679073 carriers had significantly lower frequency of MCI in a 4‐year follow‐up study, suggesting that the variant may have a neuroprotective effect on cognitive functions.
- 15 June 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (9) , 2874-2878
Parkinson's disease genome‐wide association study‐linked PARK16 variant is associated with a lower risk of cognitive impairment: A 4‐year observational study
Background and purpose: A genome‐wide association study‐linked variant (PARK16 rs6679073) modulates the risk of Parkinson's disease (PD). We postulate that there may be differences in clinical characteristics between PARK16 rs6679073 carriers and noncarriers. In a prospective study, we investigate the clinical characteristics between PARK16 rs6679073 A allele carriers and noncarriers over 4 years.Methods: A total of 204 PD patients, comprising 158 PARK16 rs6679073 A allele carriers and 46 noncarriers, were recruited. All patients underwent motor and nonmotor symptom and cognitive assessments yearly over 4 years.Results: PARK16 rs6679073 carriers were less likely to have mild cognitive impairment (MCI) compared to noncarriers at both baseline (48.1% vs. 67.4%, p = 0.027) and 4‐year follow‐up (29.3% vs. 58.6%, p = 0.007).Conclusions: PD PARK16 rs6679073 carriers had significantly lower frequency of MCI in a 4‐year follow‐up study, suggesting that the variant may have a neuroprotective effect on cognitive functions.
- 1 February 2020
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 72, 63-67
Prognostic factors of key outcomes for motor neuron disease in a multiracial Asian population
- 1 February 2020
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 72, 63-67
Prognostic factors of key outcomes for motor neuron disease in a multiracial Asian population
- Open Access
- 21 June 2019
- Published by Springer Nature in Research Square
Prognostic factors of key outcomes for motor neuron disease in a multiracial Asian population
Objective To determine potential prognostic factors for survival, need for feeding and ventilation support in motor neuron diseases (MND) patients in a multi-racial Asian population. Methods One hundred and four MND patients from the Singapore General Hospital (SGH) between January 2004 and December 2017 were reviewed. All relevant clinical data, demographic information were collected. Kaplan-Meier and cox regression model were performed to identify potential prognostic factors for crucial outcomes (survival, need for feeding support and ventilation support). Results Mean age of onset was 59.54± 10.91 years, Mean age of onset in Malays was significantly younger than that of other ethnic groups (Malay: 54.18±12.95years; Non-Malay: 60.39±10.38years, p=0.035). Fifty six of the male and 33of the female were diagnosed with ALS (90.3% vs 78.6% p=0.048). Mean overall survival duration from symptom onset was significantly longer in female than male patients (female: 39.2± 29.04 months; male: 29.4± 24.06months, P=0.03). Bulbar onset was a significant risk predictor for both the need of feeding support (HR=3.87, p<0.001) and respiratory aid (HR=3.43, p=0.01).A longer interval from symptom onset to diagnosis was correlated with a longer time to the need for feeding support (HR=0.94, p=0.002) and respiratory aid (HR=0.9, p=0.009). In the univariable cox regression analysis, need for respiratory support (HR=2.1, p=0.03) indicated poor survival outcome significantly, while MND subtypes other than ALS (HR=0.25, p=0.008) and slower disease progression, including longer duration from symptom onset to second symptom (HR=0.97, p=0.005), to feeding support (HR=0.95, p<0.001), to ventilation support (HR=0.96, p=0.004), significantly suggested lower risk of death. In the multivariable cox regression model, bulbar onset (aHR=5.28, p=0.035) correlated with poor survival outcome while longer duration from onset to second symptom (aHR=0.96, P=0.037) indicated better survival. Conclusions Bulbar onset was a significant risk predictor for survival, need of feeding support and ventilation aid. Slower disease progression correlated with better outcomes. Age of onset may differ among ethnic groups. Male patients are more likely to develop ALS and have shorter survival duration.
- 21 June 2019
- Published by Springer Nature in Research Square
Open AccessPrognostic factors of key outcomes for motor neuron disease in a multiracial Asian population
Objective To determine potential prognostic factors for survival, need for feeding and ventilation support in motor neuron diseases (MND) patients in a multi-racial Asian population. Methods One hundred and four MND patients from the Singapore General Hospital (SGH) between January 2004 and December 2017 were reviewed. All relevant clinical data, demographic information were collected. Kaplan-Meier and cox regression model were performed to identify potential prognostic factors for crucial outcomes (survival, need for feeding support and ventilation support). Results Mean age of onset was 59.54± 10.91 years, Mean age of onset in Malays was significantly younger than that of other ethnic groups (Malay: 54.18±12.95years; Non-Malay: 60.39±10.38years, p=0.035). Fifty six of the male and 33of the female were diagnosed with ALS (90.3% vs 78.6% p=0.048). Mean overall survival duration from symptom onset was significantly longer in female than male patients (female: 39.2± 29.04 months; male: 29.4± 24.06months, P=0.03). Bulbar onset was a significant risk predictor for both the need of feeding support (HR=3.87, p<0.001) and respiratory aid (HR=3.43, p=0.01).A longer interval from symptom onset to diagnosis was correlated with a longer time to the need for feeding support (HR=0.94, p=0.002) and respiratory aid (HR=0.9, p=0.009). In the univariable cox regression analysis, need for respiratory support (HR=2.1, p=0.03) indicated poor survival outcome significantly, while MND subtypes other than ALS (HR=0.25, p=0.008) and slower disease progression, including longer duration from symptom onset to second symptom (HR=0.97, p=0.005), to feeding support (HR=0.95, p<0.001), to ventilation support (HR=0.96, p=0.004), significantly suggested lower risk of death. In the multivariable cox regression model, bulbar onset (aHR=5.28, p=0.035) correlated with poor survival outcome while longer duration from onset to second symptom (aHR=0.96, P=0.037) indicated better survival. Conclusions Bulbar onset was a significant risk predictor for survival, need of feeding support and ventilation aid. Slower disease progression correlated with better outcomes. Age of onset may differ among ethnic groups. Male patients are more likely to develop ALS and have shorter survival duration.
- Open Access
- 27 February 2019
- Published by BMJ in Journal of Medical Genetics
- Vol. 56 (11) , 765-768
Parkinson’s disease GWAS-linked Park16 carriers show greater motor progression
Background Data on the long-term motor outcomes of genome-wide association study (GWAS)-linked Parkinson disease (PD) carriers are useful for clinical management. Objectives To characterise the association between GWAS-linked PARK16 gene variant and disease progression in PD over a 9-year time frame. Methods Over a 9-year period, carriers of PARK16 rs11240572 variant and non-carriers were followed up and evaluated using the modified Hoehn and Yahr (H&Y) staging scale and Unified Parkinson’s Disease Rating Scale (UPDRS) part III. A longitudinal, linear mixed model was performed to compare the changes of H&Y staging scale, UPDRS motor score and UPDRS subscores between the two groups. Results A total of 156 patients (41 PARK16 carriers and 115 non-carriers) were evaluated and followed up for up to 9 years. Using longitudinal linear mixed model analysis, there was a greater rate of deterioration in the motor function as measured by the UPDRS scores compared with non-carriers after 5 years from the date of diagnosis (p=0.009). In addition, we demonstrated that PARK16 variant carriers had worse gait scores (p=0.043) and greater motor progression than non-carriers after 6 years based on the modified H&Y staging scale (p=0.040). Conclusions In a 9-year longitudinal study, we demonstrated that PD PARK16 variant carriers exhibited greater motor progression after 5 years of disease compared with non-carriers, suggesting that GWAS-linked gene variants may influence disease progression over time. Closer monitoring and management of these higher risk patients can facilitate a better quality of life.
- 27 February 2019
- Published by BMJ in Journal of Medical Genetics
- Vol. 56 (11) , 765-768
Open AccessParkinson’s disease GWAS-linked Park16 carriers show greater motor progression
Background Data on the long-term motor outcomes of genome-wide association study (GWAS)-linked Parkinson disease (PD) carriers are useful for clinical management. Objectives To characterise the association between GWAS-linked PARK16 gene variant and disease progression in PD over a 9-year time frame. Methods Over a 9-year period, carriers of PARK16 rs11240572 variant and non-carriers were followed up and evaluated using the modified Hoehn and Yahr (H&Y) staging scale and Unified Parkinson’s Disease Rating Scale (UPDRS) part III. A longitudinal, linear mixed model was performed to compare the changes of H&Y staging scale, UPDRS motor score and UPDRS subscores between the two groups. Results A total of 156 patients (41 PARK16 carriers and 115 non-carriers) were evaluated and followed up for up to 9 years. Using longitudinal linear mixed model analysis, there was a greater rate of deterioration in the motor function as measured by the UPDRS scores compared with non-carriers after 5 years from the date of diagnosis (p=0.009). In addition, we demonstrated that PARK16 variant carriers had worse gait scores (p=0.043) and greater motor progression than non-carriers after 6 years based on the modified H&Y staging scale (p=0.040). Conclusions In a 9-year longitudinal study, we demonstrated that PD PARK16 variant carriers exhibited greater motor progression after 5 years of disease compared with non-carriers, suggesting that GWAS-linked gene variants may influence disease progression over time. Closer monitoring and management of these higher risk patients can facilitate a better quality of life.
- 20 April 2015
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 5 (2) , 147-153
Nonmotor Symptoms in Sporadic Versus Familial Forms of Parkinson’s Disease
Besides the classical motor symptoms, Parkinson's disease (PD) patients experience a wide range of nonmotor symptoms (NMS) throughout the disease course. However, due to the lack of recognition and understanding of the pathogenesis, NMS symptoms may be overlooked. Familial PD is a well-defined group that can provide a good model to investigate the mechanisms for both motor and NMS in PD. Some studies suggest that the frequency of NMS is not different between genetic and sporadic form of PD while others suggest that specific domains (such as neuropsychiatric symptoms) are more common in the genetic form. Early recognition of NMS may facilitate early diagnosis and monitoring of both sporadic and genetic PD.
- 20 April 2015
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 5 (2) , 147-153
Nonmotor Symptoms in Sporadic Versus Familial Forms of Parkinson’s Disease
Besides the classical motor symptoms, Parkinson's disease (PD) patients experience a wide range of nonmotor symptoms (NMS) throughout the disease course. However, due to the lack of recognition and understanding of the pathogenesis, NMS symptoms may be overlooked. Familial PD is a well-defined group that can provide a good model to investigate the mechanisms for both motor and NMS in PD. Some studies suggest that the frequency of NMS is not different between genetic and sporadic form of PD while others suggest that specific domains (such as neuropsychiatric symptoms) are more common in the genetic form. Early recognition of NMS may facilitate early diagnosis and monitoring of both sporadic and genetic PD.